Summary One hundred and seventeen patients with cerebral glioma (Kernohan grades III and IV) were treated with adjuvant chemotherapy using procarbazine (PCB), CCNU and vincristine (VCR) following whole head irradiation. Cell cultures were prepared from 40 patients in this series and their sensitivity to each cytotoxic drug was assessed in a mictotitration assay with 35 S-methionine incorporation as the end point. Twenty-two of forty (55%) patients responded to PCB and/or CCNU in vitro, and sensitivity to these drugs was linked with increased RFI, whilst sensitivity to VCR was not. The RFI of patients who had responded to PCB or CCNU in vitro was significantly longer than the RFI of patients whose tumours failed to respond in vitro or patients who had not been tested. There was no difference in sex ratio, extent of operation, radiation dose and degree of steroid cover between responders, non-responders and untested groups. Grade III tumours tended to be more sensitive in vitro than grade IV tumours. The age of patients also influenced in vitro chemosensitivity. Patients with chemosensitive tumours in vitro tended to be younger than patients with insensitive tumours in vitro. Further statistical analysis, taking into account these prognostic factors, indicated an association between chemosensitivity in vitro and RFI.
variation in response to chemotherapy amongst patients with otherwise similar tumours. Attempts to investigate this problem in the laboratory using a variety of in vitro and in vivo techniques (Gazso & Afra, 1969; Mealey et al., 1974; Kornblith & Szypko, 1978; Easty & Wylie, 1963; Saez et al., 1977; Rosenblum et al., 1978 Rosenblum et al., , 1983 Shapiro et al., 1979; Bullard et al., 1981b) have all demonstrated that human gliomas display considerable variation in chemosensitivity. In this report we present data produced with a rapid 35 S-methionine uptake assay (Darling & Freshney & Dendy, ,1983) where the end-point has been measured by scintillation autofluorography (Thomas et al., 1979; Morgan et al., 1983) which permits a rapid, objective comparison of in vitro and clinical data.
Materials and methods
Cell culture and chemosensitivity assay Biopsy samples were taken at operation for routine diagnostic neuropathological examination. Histology was reported by consultant neuropathologists at The National Hospitals, Queen Square or Maida Vale as either grade III or grade IV malignant glioma. Of 48 biopsies submitted for tissue culture, 40 (83%) were evaluable for chemosensitivity. Two (4%) became contaminated and 6 (12.5%) cases failed to grow in culture. Samples were collected in Ham's F-10 culture medium supplemented with 100 u ml-1 penicillin, 100 jigml-1 streptomycin and buffered with 20mM HEPES. Cell culture and the chemosensitivity assay have both been described in detail previously (Thomas et al., 1979; Morgan et al., 1983) . Briefly, cells at passage level 1 or 2 were diluted to 1-5 x I05cells ml -inoculated onto 96-well microtitration plates (1-5 xl04 cells/well) and incubated at 37°C for 24-72 h. Stock drug solutions were made up as follows: VCR (Oncovin, Eli Lilly) 00 jMgml-1; PCB (Natulan, Roche) 500 Mg ml -in
Ham's F-10 medium and CCNU (Lundbeck) 100jug ml-I in absolute ethyl alcohol, and subsequently stored at -80°C. Drug solutions were all diluted in Ham's F-10 plus 10% foetal calf serum, with 50 u ml -penicillin, 50 ,ug ml-1 streptomycin and buffered with 20mM HEPES. At the time of testing, 0.2 ml of each drug dilution was added to the appropriate wells and renewed 24 and 48 h later to give a total exposure time of 72 h. The concentration ranges of drugs used in this study has been published together with their relationship to the in vivo concentrations attainable (Morgan et al., 1983) . Finally, the drugs were removed and each well gently washed and filled with 0.2 ml of fresh growth medium. After 3-5 days recovery period, 0.1 ml of 2 pCi ml-I of 35 S-methionine was added to each well, and incubated for 4-18h. The plates were then washed in Hanks' buffered saline, fixed in methanol, extracted in trichloroacetic acid, washed in tap water and dried in methanol.
Toluene-based scintillation fluid (50pl) was added to each well and the plates were dried by centrifugation. A sheet of X-ray film was then placed under each plate and exposed for between 24h and 2 weeks. Each column of the developed negative was scanned with a densitometer and the ID50 (the dose of the drug which inhibited protein synthesis by 50%) was determined from the densitometer traces (Thomas et al., 1979) .
Previous studies with HeLa cells (Freshney et at., 1975) have shown that prolonged exposure to drugs followed by recovery were necessary to obtain stable ID50 values for most drugs, especially phase specific agents. Therefore, in order to minimise internal variation in the assay, cultures were sampled after 3-5 days recovery but before density limitation of growth occurred (Morgan et al., 1983) . At this point, the ID50 measured by clonogenicity and microtitration assay correlate well (Morgan et al., 1983) . The ID50 of each glioma cell culture was determined and compared to a panel of 123 cultures derived from tumours of the same histology that had been assayed for chemosensitivity to PCB, CCNU and VCR in this laboratory using the same assay. Sensitivity was defined as an ID50 below the median ID50 of the panel of cultures. If the ID50 was above the median for the group then the culture was designated a non-responder.
Patients
One hundred and seventeen patients (see Table II ) with histologically verified malignant gliomas were treated post operatively with a combination of radiotherapy and chemotherapy. Radiation was administered either to the whole brain, or to a complete hemisphere with appropriate overlap to include possible extension into the opposite hemisphere. The tumour minimum dose was 40-60 Gy. Steroid therapy with dexamethasone or betamethasone was used as necessary to control raised intracranial pressure, but at the lowest maintenance dose consistent with good medical management and stopped, in most cases, as soon as radiation treatment had been completed. It was only reintroduced when signs and symptoms were indicative of tumour recurrence. From 2-6 weeks after the completion of radiation therapy, patients began chemotherapy, on an outpatient basis, consisting of VCR, 1.4 mgm-2 as a single dose, CCNU, 80 mg m-2 as a single dose, orally, and PCB, orally, 100mgm-2 per day over 10 days. Patients were reviewed clinically and haematologically every 6 weeks on an outpatient basis. Patients were treated for 12 cycles over an 18-month period. Computerized tomography (CT) was performed routinely approximately every 3 months during active therapy and every 6 months following its completion. The time from surgery until disease progression was termed the relapse free interval (RFI). Disease progression was defined as a marked deterioration in clinical status, which was in most, but not all cases, accompanied by a worsening in the CT scan. The criteria for deterioration used in this study were similar to those described by Levin et al. (1977) except that electroencephalographic recordings and radionuclide scanning were not routinely performed. Relapse free interval was chosen in this study rather than survival as extensive use of high dose glucocorticoids to control cerebral oedema can prolong survival considerably even in the face of obvious tumour recurrence. To be included in this study, all patients must have received a full course of radiotherapy and at least one course of chemotherapy. Patients were selected for the study purely on clinical grounds and it was not necessary for a tissue culture sample to have been taken or a chemosensitivity assay to have been carried out for a patient to receive chemotherapy. All clinical/in vitro correlations were carried out retrospectively, and no attempt was made to influence chemotherapy using the results of the assay.
Results
Each patient whose cells were assayed was designated a responder or non-responder to a particular drug on the criteria described in the methods section. 14/40 (35%) of (Mantel, 1966) 77 patients who had not been tested for chemosensitivity (Group C). Figure 1 shows the Kaplan-Meier survival plots (Kaplan & Meier, 1958) for the relapse-free intervals of these groups. The chemosensitive group (A) remained relapse-free for longer than the non-chemosensitive group B (Mantel-Cox test, P<0.0001). The RFIs of those patients whose cells had been tested in vitro (A+B) were compared with the RFIs for the untested group, C, and no significant difference was found (P= 0.28).
To ascertain whether the improved RFI in the chemosensitive group could be explained as a function of variation in other prognostic factors, a comparison was made between the groups on a number of possible prognostic factors (Table II) Further tests were done to see, in the whole sample, the effect of each of the prognostic factors on RFI (Table III) C and those patients who had been tested (groups A and B). However, amongst those tested a higher proportion of parietal tumours were not sensitive in vitro.
For groups A and B, Cox's proportional hazard model (PHM) (Cox, 1972) was fitted using a forward stepwise procedure and including in the model, age, grade, site of tumour, chemosensitivity and including all interactions up to the third order. The final model showed that when all other factors were taken into account chemosensitivity was still related to longer RFI.
To check that the similarity in RFI in the tested and untested groups was not because an actual difference was masked by variations in age, grade or site, a Cox PHM was fitted including these factors. When the effect of age, grade and site were taken into account there was still no difference in RFI between the tested (A+B) and the untested (C) groups.
Discussion
The triple agent regimen of PCB, CCNU and VCR has evolved from initial studies by Gutin et al. (1975) and Shapiro & Young (1976) who combined three agents which had been reported as modestly successful single agents for the treatment of glioma. All three agents are capable of passing the bloodbrain barrier and therefore might be expected to pass not only into the body of the tumour but also into the tumour periphery with its infiltrating edge. Experimental evidence (Rosenblum et al., 1976) suggests that administering cycle specific agents such as vincristine after treatment with CCNU and PCB might enhance maximum cell kill during a period when tumour cells should be rapidly proliferating.
From our study we have demonstrated that patients do not respond to these agents in the same way. It is possible to divide patients into two groups, those whose tumours respond to PCB or CCNU in vitro and those whose tumours do not. Morphologically similar tumours do not always uniformly respond to single therapeutic agents. Usually this is ascribed to vague factors such as host-tumour interaction or differences in regional drug delivery. Recent experimental work, has, however, strongly suggested that the intrinsic variation in chemosensitivity among individual tumours may be one factor which is responsible for these patterns of response. Detailed in vitro studies (Darling & Thomas, in preparation) indicate that glioma cell cultures demonstrate considerable heterogeneity in response to not only PCB, CCNU and VCR but also to other agents such as adriamycin, VP 16-213, AZQ, bleomycin and 5-FU. Shapiro et al. (1981) and Yung et al. (1982) have demonstrated that clones from a single glioma biopsy display differing chemosensitivities in vitro. colleagues (1978, 1981) The apparent ineffectiveness of vincristine in prolonging relapse free interval is rather unexpected in light of a number of reports indicating its modest effect as a single agent . Vincristine does appear to be particularly effective against rapidly growing intracranial tumours such as medulloblastomas (Crafts et al., 1978) . In malignant gliomas which have relatively small growth fractions (often < 10%, Steel, 1980) vincristine may well be less effective than cycle nonspecific drugs like nitrosoureas and procarbazine. As the chemosensitivity assay uses exponentially dividing cells in situ sensitivity may be overpredicted because of the relative insensitivity on non-cycling cells in situ. As CCNU and procarbazine are not restricted in their effectiveness by cell cycle constraints the in situ effectiveness of these drugs will be demonstrable in either cycling or non-cycling cells.
It may be that vincristine cannot penetrate into the actively growing periphery of the tumour because of a partially intact blood-brain barrier. Evidence from animal experiments using intracranial tumour models indicates that the brain adjacent to the tumour (BAT) is less permeable to hydrophilic molecules than normal brain while remaining freely permeable to lipophilic drugs (Levin et al., 1975 (Kornblith et al., 1981) . The effect of patient age on in vitro chemosensitivity has already been examined by Rosenblum et al. (1982) who found an inverse correlation between sensitivity to BCNU in vitro and the patients age. Patients with sensitive cells tended to be younger than those patients with resistant cells. From our data it is also apparent that within the tested groups (A + B), fewer parietal tumours are sensitive in vitro (Table II) , and this results in an overall poorer prognosis for patients with parietal tumours in the group as a whole. A detailed examination of the Brain Tumor Study Group data has failed to confirm that patients with parietal tumours have a worse prognosis than patients with tumours in other locations (Byar et al., 1983) .
The association between in vitro chemosensitivity and RFI demonstrated in this study is in accordance with studies which have shown a correlation between in vitro drug sensitivity and survival of patients with ovarian cancer (Alberts, 1981) and multiple myeloma (Durie et al., 1983) . In a study of patients with relapsed ovarian cancer, Alberts (1981) has shown that those patients treated with drugs to which they were sensitive in the assay had significantly longer survival times than those patients who were either resistant in the assay or sensitive but were treated empirically with drugs not recommended by the assay. In this study, care was taken to see that these differences in survival were not simply due to an imbalance of prognostic factors between groups.
The present study found that length of RFI of patients with malignant gliomas undergoing adjuvant chemotherapy is linked with sensitivity to PCB and CCNU in vitro. Although other prognostic signs do influence clinical outcome, statistical analysis confirms in vitro chemosensitivity as a factor in determining relapse free interval. The next stage is to use this assay to carry out a prospective trial of chemosensitivity testing for malignant gliomas.
